Skip to main content
Article thumbnail
Location of Repository

γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein

By Natalia Ninkina, Owen Peters, Steven Millership, Hatem Salem, Herman van der Putten and Vladimir L. Buchman

Abstract

The role of α-synuclein in pathogenesis of familial and idiopathic forms of Parkinson’s disease, and other human disorders known as α-synucleinopathies, is well established. In contrast, the involvement of two other members of the synuclein family, β-synuclein and γ-synuclein, in the development and progression of neurodegeneration is poorly studied. However, there is a growing body of evidence that α-synuclein and β-synuclein have opposite neuropathophysiological effects. Unlike α-synuclein, overexpressed β-synuclein does not cause pathological changes in the nervous system of transgenic mice and even ameliorates the pathology caused by overexpressed α-synuclein. To assess the consequences of excess expression of the third family member, γ-synuclein, on the nervous system we generated transgenic mice expressing high levels of mouse γ-synuclein under control of Thy-1 promoter. These animals develop severe age- and transgene dose-dependent neuropathology, motor deficits and die prematurely. Histopathological changes include aggregation of γ-synuclein, accumulation of various inclusions in neuronal cell bodies and processes, and astrogliosis. These changes are seen throughout the nervous system but are most prominent in the spinal cord where they lead to loss of spinal motor neurons. Our data suggest that down-regulation of small heat shock protein HSPB1 and disintegration of neurofilament network play a role in motor neurons dysfunction and death. These findings demonstrate that γ-synuclein can be involved in neuropathophysiological changes and the death of susceptible neurons suggesting the necessity of further investigations of the potential role of this synuclein in disease

Topics: Articles
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2671987
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2006). A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes.
    2. (2000). A new variant of Charcot–Marie–Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.
    3. (2004). Accumulation of betaand gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse.
    4. (2007). Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.
    5. (2008). Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes.
    6. (2005). Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.
    7. (1998). Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies.
    8. (2001). Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease.
    9. (2004). An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.
    10. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.
    11. (1999). Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
    12. (2001). b-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.
    13. (2001). Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease.
    14. (2003). Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson’s disease.
    15. (2003). Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson’s disease.
    16. (2006). Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
    17. (2002). Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    18. (2008). Cell systems and the toxic mechanism(s) of alpha-synuclein.
    19. (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation.
    20. (2007). CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.
    21. (2004). Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice.
    22. (2002). Development of a new treatment for 1792 Human Molecular Genetics,
    23. (2004). Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    24. (2002). Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.
    25. (2004). Discrete gene sets depend on POU domain transcription factor Brn3b/Brn-3.2/POU4f2 for their expression in the mouse embryonic retina.
    26. (2007). Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot– Marie–Tooth disease-linked mutations in NFL and HSPB1.
    27. (2003). Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment.
    28. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    29. (2004). Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.
    30. (2002). Effects of Charcot– Marie–Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation.
    31. (2000). Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.
    32. (2000). Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit.
    33. (2004). Functions of intermediate filaments in neuronal development and disease.
    34. (2001). Further evidence that neurofilament light chain gene mutations can cause Charcot–Marie–Tooth disease type 2E.
    35. (2003). Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein.
    36. (2004). Hsp70 reduces alpha-synuclein aggregation and toxicity.
    37. (2002). Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 –. Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    38. (2008). In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson’s disease?
    39. (2000). Induction of neuronal death by alpha-synuclein.
    40. (2005). Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
    41. (2006). Mechanisms and models of alpha-synuclein-related neurodegeneration.
    42. (2002). Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
    43. (2008). Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies—is the juice worth the squeeze?
    44. (2003). Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    45. (2005). Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration.
    46. (2004). Mutant small heat-shock protein 27 causes axonal Charcot– Marie–Tooth disease and distal hereditary motor neuropathy.
    47. (2000). Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.
    48. (2002). Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
    49. (2006). Neuronal intermediate filaments and ALS: a new look at an old question.
    50. (2003). Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene.
    51. (2000). Neuropathology in mice expressing human alpha-synuclein.
    52. (2000). Parkinson’s disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
    53. (2003). Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
    54. (1998). Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system.
    55. (1998). Persyn, a member of the synuclein family, influences neurofilament network integrity.
    56. (2004). Phenotypic analysis of neurofilament light gene mutations linked to Charcot–Marie–Tooth disease in cell culture models.
    57. (2002). Pick’s disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus.
    58. (2008). Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma.
    59. (2008). Protective Human Molecular Genetics,
    60. (2007). Residual structure, backbone dynamics, and interactions within the synuclein family.
    61. (2008). Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model.
    62. (2001). Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
    63. (2007). Sequence determinants for amyloid fibrillogenesis of human alpha-synuclein.
    64. (2002). Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve.
    65. (2005). Temporal profiles of neuronal degeneration, glial proliferation, and cell death in hNFL(þ/þ) and NFL(2/2) mice.
    66. (2003). Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.
    67. (2008). Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    68. (2006). Transgenic mouse models of amyotrophic lateral sclerosis.
    69. (2003). Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
    70. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS.
    71. (1999). Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis.
    72. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.